Vaxart announces Q4 2024 financial results and trials

Vaxart, Inc. held its fourth quarter and full year 2024 earnings call today. The call featured key executives, including CEO Steven Lo, Founder Dr. Sean Tucker, and CFO Phillip Lee. During the call, Ed Berg, the Senior Vice President and General Counsel, reminded everyone that some statements made might be forward-looking. These could include insights about the company's financial results, business plans, and product development. He noted that actual results could differ due to various risks, especially in clinical trials and regulatory processes. CEO Steven Lo then took the floor to discuss Vaxart's current status and future strategies. The company aims to advance its product development while navigating challenges in the clinical landscape. A question-and-answer session will follow their opening statements. Investors can send questions via email. The call is also being recorded for reference.